Lyon Street Capital LLC acquired a new stake in Immunomedics, Inc. (NASDAQ:IMMU) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 150,000 shares of the biopharmaceutical company’s stock, valued at approximately $2,097,000. Lyon Street Capital LLC owned about 0.10% of Immunomedics at the end of the most recent reporting period.
Other large investors also recently modified their holdings of the company. Amalgamated Bank grew its holdings in Immunomedics by 8.1% in the second quarter. Amalgamated Bank now owns 12,911 shares of the biopharmaceutical company’s stock worth $114,000 after purchasing an additional 966 shares during the period. Stephens Inc. AR bought a new position in shares of Immunomedics in the second quarter valued at $115,000. Raymond James Financial Services Advisors Inc. lifted its stake in shares of Immunomedics by 11.4% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 14,400 shares of the biopharmaceutical company’s stock valued at $127,000 after buying an additional 1,473 shares in the last quarter. SG Americas Securities LLC lifted its stake in shares of Immunomedics by 99.3% in the second quarter. SG Americas Securities LLC now owns 20,719 shares of the biopharmaceutical company’s stock valued at $183,000 after buying an additional 10,323 shares in the last quarter. Finally, Legal & General Group Plc lifted its stake in shares of Immunomedics by 7.4% in the second quarter. Legal & General Group Plc now owns 25,477 shares of the biopharmaceutical company’s stock valued at $222,000 after buying an additional 1,747 shares in the last quarter. 76.32% of the stock is owned by institutional investors and hedge funds.
In related news, Director Brian A. Markison sold 8,390 shares of the firm’s stock in a transaction on Monday, November 20th. The stock was sold at an average price of $11.89, for a total value of $99,757.10. Following the completion of the sale, the director now directly owns 99,178 shares in the company, valued at $1,179,226.42. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Venbio Select Advisor Llc bought 1,150,000 shares of the firm’s stock in a transaction dated Tuesday, November 14th. The shares were acquired at an average price of $10.39 per share, with a total value of $11,948,500.00. The disclosure for this purchase can be found here. 6.60% of the stock is owned by corporate insiders.
Shares of Immunomedics, Inc. (NASDAQ IMMU) traded up $0.18 during mid-day trading on Friday, reaching $12.41. 3,325,400 shares of the company traded hands, compared to its average volume of 3,149,292. Immunomedics, Inc. has a one year low of $3.30 and a one year high of $14.48. The company has a current ratio of 0.74, a quick ratio of 0.74 and a debt-to-equity ratio of -0.29.
Immunomedics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.
Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.